Coherus Biosciences News and Activities
Presence
Coherus Biosciences develops and sells biologic medicines for cancer care and other serious diseases. Its products and services support hospitals, clinics, and healthcare providers that need lower-cost treatment options.
Coherus Biosciences products and services overview:
- Biosimilar medicines
- Cancer therapies
- Immunotherapy products
- Drug development
- Commercial biopharma
Revenue: ~$260 million
Employees: 330
Headquarters: Redwood City, United States (USA)
Coherus Biosciences is one of the...
Coherus Biosciences is a company listed under the stock ticker CHRS (US).
Executives
View the org chart displaying its 30 main executives
Most searched biographies at Coherus Biosciences
- Dennis Lanfear, President, Chairman and Chief Executive Officer
- Ali Satvat, Director
- Jill O'Donnell-Tormey, Director
Popular executive movements at Coherus Biosciences
- Dawn Wise, Senior Director, Product Development, has left the company (posted on April 3 2026).
Create your alert
to follow the executive moves at Coherus Biosciences.
Biotechnology
Coherus Biosciences has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
Popular contacts in Biotechnology
News
Press releases by Coherus Biosciences
- FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity | Coherus BioSciences, Inc.
- Coherus BioSciences Announces New Employment Inducement Grants | Coherus BioSciences, Inc.
- Coherus BioSciences to Report Second Quarter 2022 Financial Results on August 4th, 2022 | Coherus BioSciences, Inc.
- Coherus and Junshi Biosciences Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma | Coherus BioSciences, Inc.
- Coherus BioSciences Announces New Employment Inducement Grants | Coherus BioSciences, Inc.
- Coherus BioSciences Appoints Dr. Jill O’Donnell-Tormey to its Board of Directors | Coherus BioSciences, Inc.
- Coherus BioSciences Management to Present at Upcoming Investor Conferences | Coherus BioSciences, Inc.
- Coherus BioSciences Reports First Quarter 2022 Results | Coherus BioSciences, Inc.
- Coherus BioSciences Appoints Charlie Newton to Board of Directors | Coherus BioSciences, Inc.
- Coherus BioSciences Announces New Employment Inducement Grants | Coherus BioSciences, Inc.
- View more press releases Close
Social media about Coherus Biosciences
- Coherus Biosciences on Wikipedia, Google News & Yahoo Finance
- Coherus Biosciences on LinkedIn, X (Twitter) & YouTube
